Posted in | News | Nanobusiness

Researchers Can Now Directly Profile up to 800 Transcripts in a Single Tube

NanoString Technologies, Inc., a privately held life sciences company marketing a novel digital molecular barcoding technology for detecting and counting large sets of targets in biological samples, today announced that it has increased the throughput of its nCounter® Analysis System by expanding its multiplexing capacity to 800 gene transcripts per reaction.

This additional capability allows for the high-resolution analysis of 250 additional targets from the same amount of sample, thereby increasing the efficiency of experiments and enabling researchers to perform studies not feasible using other technologies.

.With a growing interest in evaluating complex cellular interactions across large numbers of biological samples, scientists are seeking solutions capable of efficiently analyzing defined sets of targets at very high resolution. The nCounter Analysis System is meeting this need by providing a simple workflow, multiplexing, and direct detection and counting of individual RNA transcripts. The application of this technology to elucidate complex biological systems in cancer, developmental biology and cell signaling is demonstrated in a series of recent journal publications (for more information see:

“One of the important reasons customers choose the nCounter Analysis System is that it provides gold-standard molecular quantification in a highly multiplexed format, and it is easier to use than other technology platforms,” said Brad Gray, President and CEO, NanoString Technologies. “With the new multiplexing capacity, it’s as though you are performing 800 qPCR reactions in a single tube with only four pipetting steps.”

The nCounter Analysis System is widely used for gene signature validation, translational research, pathway analysis, and validation of microarray and next-generation sequencing. It includes a fully automated Prep Station, a Digital Analyzer, the CodeSet (molecular barcodes) and all reagents needed to perform the analysis. The nCounter System offer protocols starting with as little as 100ng of material from a variety of specimen types including FFPE samples, cell lysate, whole-blood lysate, and total RNA. In addition to solutions for gene expression analysis, custom and off-the-shelf assay panels are available for miRNA profiling and genomic copy number variation detection. More information is available at

NanoString Technologies is a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanostring Technologies. (2019, February 13). Researchers Can Now Directly Profile up to 800 Transcripts in a Single Tube. AZoNano. Retrieved on March 01, 2024 from

  • MLA

    Nanostring Technologies. "Researchers Can Now Directly Profile up to 800 Transcripts in a Single Tube". AZoNano. 01 March 2024. <>.

  • Chicago

    Nanostring Technologies. "Researchers Can Now Directly Profile up to 800 Transcripts in a Single Tube". AZoNano. (accessed March 01, 2024).

  • Harvard

    Nanostring Technologies. 2019. Researchers Can Now Directly Profile up to 800 Transcripts in a Single Tube. AZoNano, viewed 01 March 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.